By TAmiRNA GmbH
To get in touch with TAmiRNA GmbH, simply fill out the form below.
Subscribe to Supplier
TAmiRNA presents miND® for absolute quantitation of NGS data to the EV community at ISEV meeting in Lyon
Vienna, Austria: MicroRNA diagnostic specialist TAmiRNA will use its inaugural appearance at the Annual Meeting of the International Society of Extracellular Vesicles (ISEV 2022), in the French city of Lyon, to showcase its unique miND® NGS workflow for characterizing the RNA cargo of EVs.
TAmiRNA will share a stand with its fellow Viennese innovator Evercyte GmbH at Booth 2, from where it will display its leading edge technology portfolio for transcriptomic analysis of EV RNA cargo.
Innovative miRNA and small RNA sequencing
The TAmiRNA event team, led by CEO and CSO Dr. Matthias Hackl and scientist Marianne Pultar MSc, will focus on presenting its recently developed miND® microRNA Next-Generation-Sequencing Discovery Assay pipeline that offers an innovative workflow for absolute quantification of miRNAs and small RNAs in various biological sample or species, including EVs and exosomes.
The technology is based on TAmiRNA’s novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data. This technology will be made available to the small RNA research community as a stand-alone product called miND® spike-ins.
Visitors to the stand will also be able to obtain a complimentary demo of the recently published miND® interactive NGS report (see Resources) as well as opportunities to purchase miND® spike-ins or utilize TAmiRNA´s miND® small RNA-sequencing services at discounted prices.
TAmiRNA will also present ISEV with a poster ‘Characterization of EV RNA cargo from primary and telomerase immortalized MSCs using a novel small RNA-seq workflow enabling absolute RNA quantification’ that explains the miND® workflow and its potential applications.
New drug targets
“We are very excited to be making our first ever appearance at the ISEV annual meeting, which is one of the top events for academics and biotech companies engaged in research and development of extracellular vesicles (EV) as biomarkers and therapeutic targets, as well as basic research,” commented Matthias Hackl.
“This is a superb opportunity to inform the EV research community about our miND® spike-ins and the related small RNA-sequencing workflow to explore the RNA cargo of EVs to understand EV biology and discover novel biomarkers or drug targets,” added Marianne Pultar.
About TAmiRNA GmbH
TAmiRNA specializes in technologies for profiling levels of blood-circulating miRNAs and developing multi-parametric classification algorithms (“signatures”). TAmiRNA uses these technologies to develop minimal-invasive diagnostic tests for drug development, early diagnosis and prognosis of disease, and as companion diagnostic tests to support treatment decisions.
For its work on circulating microRNAs in bone disease, TAmiRNA is receiving funding from the European Union’s Horizon 2020 research and innovation program under the MARIE SKŁODOWSKA-CURIE grant agreement no. 860898 and from TransBioLine project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 821283. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
More information available at: www.tamirna.com
About Evercyte GmbH
Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel production cell lines for extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.
The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalog of readily available cell lines for the production of extracellular vesicles from mesenchymal stem cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.
By providing native extracellular vesicles from mesenchymal stem cells and targeting extracellular vesicles Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs for e.g. tissue targeting and drug targeting.
Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in-vitro bioassays as well as relevant cell models and cell factories.
Learn more at: http://www.evercyte.com.
About ISEV 2019
The International Society for Extracellular Vesicles is the leading professional society for researchers and scientists involved in the study of microvesicles and exosomes.
With nearly 1,000 members, ISEV continues to be the leader in advancing the study of extracellular vesicles globally. Founded in 2012 in Sweden, ISEV is now headquartered in the USA. Through its programs and services, it provides essential training and research opportunities for those involved in exosome and microvesicle research.
The ISEV Annual Meeting attracts nearly 1,000 attendees, including top researchers in the field discussing the latest in extracellular vesicles, exosomes, and microvesicles.
ISEV 2022 is a five-day event opening May 25 at the Lyon Convention Center in southern France. .
The event is organized by ISEV, with further information at: https://www.eventscribe.net/2022/ISEV2022/
Click on TAmiRNA NGS Data (miND®) pipeline to view video.
Click on miND® spike-ins for further information.
Click on miND® small RNA-sequencing workflow for EVs for further information.
Click on miND (miRNA NGS Discovery pipeline) to access published scientific report.